Treatment with the NLRP3 inflammasome blocker MCC950 attenuated liver inflammation and fibrosis in two mouse models of NASH, that is, the Alms1 mutant (foz/foz) mice fed with an atherogenic diet and C57BL/6 mice fed with an MCD diet [17]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.